GMR Airports Gets 'Buy' Rating As Citi Initiates Coverage
Citi Research has initiated coverage on GMR Airports with a 'buy' rating, citing a strong mid-term growth outlook that justifies a valuation premium. The brokerage has set a target price of Rs 90, based on a sum-of-the-parts valuation.
GMR Airports is well-positioned to benefit from India's projected passenger volume growth, which is expected to see a compound annual growth rate of 8% over FY24-27, according to the brokerage.
The company's assets, including the Delhi airport with its four runways, are strategically placed to capture long-term growth, especially compared to the capacity-constrained Mumbai airport.
GMR Airports is forecasted to turn profitable by fiscal 2026, driven by an 8% traffic growth and a significant tariff increase at the Delhi airport. Citi expects the company's earnings for FY27 to be 5-6% above market expectations, supported by a 2.4 times tariff increase at Delhi and a 7.5% annual increase in non-aero spending per passenger, across its airports in Delhi, Hyderabad, and Goa.
Citi's target price of Rs 90 implies a 20 times FY27 EV/Ebitda, which is double the average for Asia-Pacific airports, but still lower than the 25 times seen during the peak of Chinese tourism and duty-free booms. The brokerage sees GMR Airports' strong traffic outlook, potential for increased non-aero spending, and opportunities from government airport privatisations as key growth drivers.
While Citi is optimistic about GMR Airports' prospects, it also notes potential risks, including slower-than-expected traffic growth and negative equity market conditions. However, high-single-digit traffic growth and airport privatisation rollouts will act as positive catalysts for the stock, the brokerage said.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.